title: Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
abstract: OBJECTIVE
  The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively.
  
  
  METHODS
  This study included 67 patients with pathologic TNM stage II, III, and IV. TYMS and ERCC1 mRNA expression was determined using real-time reverse transcriptase-polymerase chain reaction (RT-PCR). The chemosensitivity was examined using an ATP-based chemotherapy response assay. A high response was defined as a response producing ≥40% reduction in ATP.
  
  
  RESULTS
  The mean level of TYMS mRNA expression in the groups with low and high response to 5-FU was 2.35×10(-3) ± 2.16×10(-3) 2(-(ΔCt)) and 4.54×10(-3) ± 2.46×10(-3) 2(-(ΔCt)), respectively. The mean level of ERCC1 mRNA expression in the groups with low and high response to oxaliplatin was 13.92×10(-3) ± 9.90×10(-3) 2(-(ΔCt)) and 23.59×10(-3) ± 5.88×10(-3) 2(-(ΔCt)), respectively. Groups with high response to 5-FU and oxaliplatin had significantly higher expression of TYMS and ERCC1 mRNA, respectively (p<0.01 and p=0.01, respectively).
  
  
  CONCLUSIONS
  High expression of TYMS and ERCC1 mRNA was associated with better in vitro chemosensitivity to 5-FU and oxaliplatin, respectively, in patients with colorectal cancer.
authors: Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, Korea.
authors: Yong Beom
authors: YB
authors: Cho
authors: Hyuk Jun
authors: HJ
authors: Chung
authors: Woo Yong
authors: WY
authors: Lee
authors: Sung Ho
authors: SH
authors: Choi
authors: Hee Cheol
authors: HC
authors: Kim
authors: Seong Hyeon
authors: SH
authors: Yun
authors: Ho-Kyung
authors: HK
authors: Chun
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018279:Carcinoma, Signet Ring Cell / Q000188:drug therapy / Q000235:genetics* / Q000556:secondary; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D004720:Endonucleases / Q000235:genetics*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D011379:Prognosis; D012333:RNA, Messenger / Q000235:genetics; D060888:Real-Time Polymerase Chain Reaction; D013940:Thymidylate Synthase / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; D009944:Organoplatinum Compounds; D012333:RNA, Messenger; D000077150:Oxaliplatin; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases; D005472:Fluorouracil